Home

Intellectual Property

At Stake: Gene-Based Patents

A patent case winding its way through U.S. District Court has the potential to hinder biotechnology R&D if the judge hearing the case rules in favor of the plaintiffs, led by the American Civil Liberties Union.

Hans Sauer and Professor Chris Holman: The Role of Patents in a Pathway for the Approval of Biosimilars
BIO 2009 MEMBER SURVEY TECHNOLOGY TRANSFER AND THE BIOTECHNOLOGY INDUSTRY

The purpose of this survey was to examine the extent and importance of technology transfer and licensing activity involving biotechnology companies.

The Economic Impact of Licensed Commercialized Inventions Originating in University Research, 1996-2007
Guide to Biotechnology 2008

We have used the biological processes of microorganisms for 6,000 years to make useful food products, such as bread and cheese, and to preserve dairy products.

2007-2008 BIO Milestones

Today, the biotechnology industry is enjoying more success and influence than ever before. Our industry’s innovations continue to improve the lives of people worldwide, and the advancement of these innovations is supported by the work of BIO.

What's happening with IP at BIO?
The Economic Implications of Patent Reform

Economists have long recognized that the development and spread of economic innovations are the most powerful factors affecting how fast the U.S. economy grows and how much the incomes of most Americans will rise.

PROPOSED PATENT REFORM LEGISLATION: LIMITATIONS OF EMPIRICAL DATA USED TO INFORM THE PUBLIC POLICY DEBATE

Certain groups are calling for serious overhaul of the nation‟s patent system.

BIO's “What's at Stake” Patent Reform Ad
Apportionment of Damages Provision
Best Mode Requirements Should be Repealed
Unenforceable Defense Based on Inequitable Conducts
PTO Rulemaking
Oppose New Post-Grant Review Provision

Letters, Testimony & Comments

BIO Comments on Peruvian Biologics and Biosimilars Regulations
March 21 2013
BIO commends the Government of Peru for its endeavor to create a pathway for the approval of biological and biotechnological products....
BIO Comments on Colombia Biologics and Biosimilars Regulations
February 22 2013
BIO commends the government of Colombia for taking steps towards developing regulatory requirements for the registry of medicines of...
2013 Special 301 Submission: BIO Provides Input on Biotech IP Challenges Around the Globe
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has...
BIO Comments on INPI Guidelines for Examination of Biotechnology Patent Applications in Brazil
February 1 2013
BIO commends the INPI for their efforts to devise guidelines for examining biotechnology related inventions. Given the technological...
BIO Comments on Brazil's ANVISA Public Consultation N°66/2012
February 1 2013
BIO respectfully submits both questions and comments for the National Health Surveillance Agency’s (ANVISA) consideration on the...
More Letters, Testimony & Comments →

Press Releases

BIO Shares U.S. Trade Representative's International Patent Concerns
May 2 2013
Washington, D.C. (May 2, 2013) The Biotechnology Industry Organization (BIO) today expressed concern over specific...
Indian Supreme Court Ruling Negatively Affects Innovation
April 8 2013
Washington, D.C. (April 8, 2013) –  The Biotechnology Industry Organization (BIO) issued the following...
Innovation and The Supreme Court: Two Cases to Watch
February 11 2013
  WHAT: An inside look at two cases facing the Supreme Court of the United States: Bowman v....
BIO and ASTA Welcome Continued Support for the Accord
January 15 2013
Washington, D.C. — The Biotechnology Industry Organization (BIO) and the American Seed Trade Association (ASTA...
BIO Study Quantifies Economic Contribution of University & Non-Profit Inventions
June 21 2012
Washington, D.C. (June 21, 2012) – The Biotechnology Industry Organization (BIO) released a report on the...
More Press Releases →